a public good project by the
Synthesis
Company
of California

© 2026

Ethan Burns | doi.page

0 works0 citations0 h-index

Ethan Burns

Houston Methodist(US)Yale University(US)University of New Haven(US)Methodist Hospital(US)

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, Lymphoma Diagnosis and Treatment, Lung Cancer Treatments and Mutations, CAR-T cell therapy research, CNS Lymphoma Diagnosis and Treatment

Most-Cited Works

→ Vitamin C depletion and pressure sores in elderly patients with femoral neck fracture.(1992)88 cited
→ Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors(2020)69 cited
→ Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management(2021)36 cited
→ Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors(2021)34 cited
→ Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review(2019)26 cited
→ Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II)(2021)21 cited

→ Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy(2021)

20 cited

→ Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy(2022)19 cited

→ Trends in the Body Mass Index of Pediatric and Adult Patients Undergoing Anterior Cruciate Ligament Reconstruction(2018)18 cited

→ A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)(2019)13 cited